| Next 10 |
Ad
ENOV Articles Enovis Corporation
home / stock / enov / enov articles
Articles | Enovis Corporation (NYSE:ENOV)
-
The medical info systems industry is set to thrive in the second half of 2024 due to the growing demand for contactless services. The industry witn...
-
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
-
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
-
William Bliar has initiated coverage on Enovis Corp (NYSE: ENOV), a medical technology company focusing on the orthopedics market va...
-
WILMINGTON, Del., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV, "Enovis" or the "Company")) an innovation-driven, med...
-
Needham analyst Mike Matson reiterated the Buy rating on Enovis Corporation (NYSE: ENOV), raising the price target to $70 from ...
-
Brady R. Shirley, current President and COO, to retire effective April 1, 2025. Louie Vogt to be promoted to Group President of Reconstructive se...
-
Wilmington, DE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth compan...
-
Wilmington, DE, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV, "Enovis" or the "Company")) today announced the pricing...
Stock Information
Get ENOV Alerts
News, Short Squeeze, Breakout and More Instantly...
Enovis Corporation Company Name:
ENOV Stock Symbol:
NYSE Market:
-3.52% G/L:
$33.255 Last:
247,412 Volume:
$33.94 Open:
$34.47 Close:
Enovis Corporation Website:
Ad
-
2025-05-18 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...
-
Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12 th ...